| |
Whole patient group
|
Histopathological confirmation
|
|---|
|
(n = 202)
|
(n = 73)
|
|---|
|
Age (years)
|
61.9 ± 14.9
|
54.2 ± 17.3
|
|
Gender (M/F)
|
120/82
|
43/30
|
|
Tumor type
a,b
| | |
|
Lung cancer
|
38
|
30
|
|
Head and neck cancer
|
22
|
14
|
|
Gastrointestinal cancerc
|
31
|
7
|
|
Breast cancer
|
21
|
4
|
|
Lymphoma
|
36
|
9
|
|
Melanoma
|
19
|
2
|
|
Multiple melanoma
|
15
|
5
|
|
Otherd
|
18
|
2
|
|
Clinical question
b
| | |
|
Diagnosis
|
22
|
10
|
|
Staging
|
20
|
11
|
|
Restaginge
|
33
|
18
|
|
Response to chemotherapy
|
58
|
6
|
|
Response to radiotherapy
|
18
|
6
|
|
Post-surgery evaluation
|
11
|
0
|
|
Surveillance
|
40
|
22
|
- Values are mean ± standard deviation.
- aTwo patients were not affected by any oncologic disease after histologic confirmation.
- bTumor type and clinical questions correspond to the groups submitted to the tumor-based and question-based analyses.
- cIncluding esophageal, gastric, and colorectal cancer.
- dGynecologic malignancy (n = 8), testicular cancer (n = 2), sarcoma (n = 3), low-differentiated neuroendocrine carcinoma (n = 4), thymoma (n = 1).
- eSuspected relapse or patients with potentially resectable metastatic disease.
